liver cirrhosis

[Galecto, Inc.] Galecto, Inc. announced it has completed enrollment in Parts II and III of its ongoing 3-part Phase Ib/IIa trial of GB1211, GULLIVER-2, in liver cirrhosis.

[Journal of Nanobiotechnology] The authors developed a tumor "cruise missile" designed to enhance the accuracy of small HCC visualization to 85.7% using combined ultrasound/photoacoustic imaging in complex liver environment, which facilitated sequential catalytic targeted therapy for small HCC.

[Scientific Reports] Researchers identified 130 genes significantly differentially expressed in non-alcoholic steatohepatitis (NASH) versus a mixed group of non-alcoholic fatty liver disease and healthy controls.

[Cell Death Discovery] To improve the effectiveness of naïve hair follicle-derived-MSC (HF-MSC) treatments on liver cirrhosis (LC), the authors used bioinformatic tools to identify an exogenous gene targeting hepatic stellate cells (HSCs) among the differentially expressed genes in LC to modify HF-MSCs.

[Scientific Reports] Investigators reported a new approach that enables the formation of self-assembled 3D spheroids of adipose-derived stem cells and murine hepatocytes via reconstituted collagen fibers.

[Obesity Reviews] Adipose-derived MSC transplantation may offer a potential therapeutic approach for the treatment of metabolic complications of obesity, but randomized controlled trials are required to establish their safety and efficacy in humans prior to routine clinical use.